Rank: 1
Ligand Number: 10
SMILES: O=[N+]([O-])c1c(Nc2ccc(Br)cc2)ccc2nonc12
Confidence Score: 0.8186
Response: Based on the predictions from the available tools, the pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(Nc2ccc(Br)cc2)ccc2nonc12 are as follows:

*   **Oral Bioavailability:** Predicted to be **low (< 20%)**. This suggests that only a small fraction of the drug administered orally would reach systemic circulation.
*   **Half-Life:** Predicted to be **99.00 hours**. This indicates a very long half-life, meaning the drug would persist in the body for an extended period, potentially allowing for less frequent dosing but also requiring careful consideration for accumulation.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be **1.00 L/kg**. This value suggests a moderate distribution throughout the body, implying it distributes beyond the plasma but not extensively into tissues.

Further comprehensive assessment of PK properties would typically include details on absorption (e.g., solubility, permeability, Lipinski's Rule of 5 properties), other aspects of distribution (e.g., plasma protein binding, blood-brain barrier penetration), metabolism (e.g., specific CYP substrate/inhibitor profile), and excretion pathways. However, these additional specific properties could not be predicted with the tools used.
============================================================
Rank: 2
Ligand Number: 7
SMILES: COc1cccc(Nc2ccc3nonc3c2[N+](=O)[O-])c1
Confidence Score: 0.8161
Response: The PK properties of the drug with the SMILES COc1cccc(Nc2ccc3nonc3c2[N+](=O)[O-])c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, indicating poor oral absorption.
*   **Half-life:** Predicted to be 1.00 hours, suggesting a very short duration of action.
*   **Steady-state Volume of Distribution (VDss):** Predicted to be 1.00 L/kg, which indicates moderate distribution into body tissues.
============================================================
Rank: 3
Ligand Number: 9
SMILES: O=[N+]([O-])c1c(Nc2ccc(Cl)cc2)ccc2nonc12
Confidence Score: 0.7220
Response: The predicted pharmacokinetic (PK) properties for the drug with the SMILES `O=[N+]([O-])c1c(Nc2ccc(Cl)cc2)ccc2nonc12` are as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**. This indicates poor oral absorption, suggesting that oral administration might not be an effective route for this drug.
*   **Half-Life (Obach Model):** Predicted to be **99.00 hours**. This signifies a very long half-life, meaning the drug would persist in the body for an extended period.
*   **Volume of Distribution at Steady State (VDss Lombardo Model):** Predicted to be **1.00 L/kg**. This suggests moderate distribution into tissues beyond the plasma volume, indicating distribution into total body water and potentially some tissues.

**Summary of PK implications:**

Given these predictions, the drug is likely to have poor oral absorption, which might necessitate alternative routes of administration (e.g., intravenous). Once absorbed, it would distribute moderately into tissues and have a very long duration of action due to its extended half-life. This long half-life could significantly impact dosing frequency and the time required to reach steady state or to be eliminated from the body.
============================================================
Rank: 4
Ligand Number: 6
SMILES: O=[N+]([O-])c1c(NCc2cc(F)ccc2C(F)(F)F)ccc2nonc12
Confidence Score: 0.6143
Response: The pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(NCc2cc(F)ccc2C(F)(F)F)ccc2nonc12, based on computational predictions, are as follows:

1.  **Oral Bioavailability:** The drug is predicted to have **oral bioavailability less than 20%**. This suggests that if administered orally, only a small fraction of the drug would reach systemic circulation. This could be due to factors such as poor absorption across the gastrointestinal tract, low solubility, or extensive first-pass metabolism in the liver.

2.  **Half-Life (tÂ½):** The predicted half-life for this drug is an extremely long **3013.00 hours**. Such a prolonged half-life indicates that the drug is eliminated very slowly from the body. This could lead to significant drug accumulation in the body with repeated dosing, and a very long time to reach steady-state concentrations or to be completely cleared after discontinuation.

3.  **Volume of Distribution at Steady State (VDss):** The predicted steady-state volume of distribution is **3.00 L/kg**. A VDss value significantly greater than 1 L/kg indicates that the drug distributes extensively into tissues outside of the plasma compartment. This suggests that the drug has a high affinity for extravascular tissues and is likely to accumulate there.

**Summary of PK Properties:**
This compound exhibits challenging pharmacokinetic properties for drug development. It is predicted to have very low oral bioavailability, which would limit its effectiveness when administered orally. Furthermore, its extremely long half-life and high volume of distribution suggest that it would persist in the body for extended periods, potentially accumulating in tissues. These characteristics have significant implications for dosing regimens, potential for systemic accumulation, and overall safety profile in a clinical setting.
============================================================
Rank: 5
Ligand Number: 4
SMILES: O=[N+]([O-])c1c(NCc2cc(F)cc(Cl)c2)ccc2nonc12
Confidence Score: 0.5781
Response: The pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(NCc2cc(F)cc(Cl)c2)ccc2nonc12 are predicted as follows:

*   **Oral Bioavailability:** The drug is predicted to have **oral bioavailability of < 20%**. This indicates very poor absorption when administered orally, suggesting that oral administration would be inefficient and likely not therapeutically viable without significant formulation efforts or alternative routes.

*   **Half-Life:** The predicted half-life (Obach model) is **303.00 hours**, which is exceptionally long. A half-life of this duration indicates that the drug would remain in the body for a very prolonged period, potentially leading to drug accumulation with repeated dosing and requiring very infrequent dosing intervals.

*   **Volume of Distribution (VDss):** The predicted steady-state volume of distribution (Lombardo method) is **3.00 L/kg**. This value suggests that the drug distributes moderately into tissues beyond the plasma compartment, indicating it's not strictly confined to the bloodstream but also not extensively sequestered in peripheral tissues like adipose tissue.

In summary, this drug exhibits a challenging PK profile for oral administration due to very low bioavailability. However, if administered via a route that bypasses first-pass metabolism, its extremely long half-life could offer the advantage of very infrequent dosing, though potential for accumulation and sustained exposure would need careful management. The moderate volume of distribution suggests a balance between plasma and tissue distribution.
============================================================
Rank: 6
Ligand Number: 8
SMILES: O=[N+]([O-])c1c(Nc2ccc(F)cc2)ccc2nonc12
Confidence Score: 0.4833
Response: The PK properties of the drug with SMILES O=[N+]([O-])c1c(Nc2ccc(F)cc2)ccc2nonc12 are predicted as follows:

*   **Oral Bioavailability:** The drug is predicted to have oral bioavailability of less than 20%, suggesting poor absorption from the gastrointestinal tract.
*   **Half-life:** The predicted half-life (Obach model) is 99.00 hours, indicating a very long duration of action.
*   **Steady-state Volume of Distribution (VDss):** The predicted VDss (Lombardo model) is 1.00 L/kg, which generally suggests moderate distribution into tissues.
============================================================
Rank: 7
Ligand Number: 17
SMILES: Ic1cccc([C@@H]2C[C@H](c3ccccc3)n3nnnc3N2)c1
Confidence Score: 0.4693
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug Ic1cccc([C@@H]2C[C@H](c3ccccc3)n3nnnc3N2)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be approximately 611.00 hours, indicating a very long duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 53.00 L/kg, which suggests extensive distribution into the tissues.
============================================================
Rank: 8
Ligand Number: 18
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H][C@@H]2F
Confidence Score: 0.4684
Response: Based on the computational predictions for the drug with the SMILES string CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H][C@@H]2F, here are its predicted pharmacokinetic (PK) properties:

*   **Oral Bioavailability:** The drug is predicted to have an oral bioavailability of less than 20%, suggesting that a significant portion of an orally administered dose may not be absorbed into the systemic circulation.
*   **Half-Life:** The predicted half-life is 1.00 hour. This indicates that the drug is eliminated relatively quickly from the body, suggesting a short duration of action.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 1.00 L/kg. This value suggests that the drug primarily distributes within the extracellular fluid compartment and does not extensively accumulate in tissues beyond the plasma and interstitial spaces.
============================================================
Rank: 9
Ligand Number: 3
SMILES: [3H]c1ccc2nonc2c1[N+](=O)[O-]
Confidence Score: 0.4285
Response: The drug provided, `[3H]c1ccc2nonc2c1[N+](=O)[O-]`, is 4-nitrobenzofuroxan, labeled with tritium (`[3H]`). The tritium label is typically used in ADME (Absorption, Distribution, Metabolism, Excretion) studies to track the compound's fate in biological systems, but the fundamental pharmacokinetic (PK) properties relate to the unlabeled parent compound.

Based on the available *in silico* predictions and a search for experimental data:

*   **Oral Bioavailability:** This drug is **predicted to have poor oral bioavailability, specifically less than 20%**. This suggests that if administered orally, a significant portion of the drug might not be absorbed into the systemic circulation.
*   **Half-Life:** The **predicted half-life is 1.00 hour**. This indicates that the drug is likely eliminated relatively quickly from the body, necessitating frequent dosing if a sustained therapeutic effect is desired.
*   **Volume of Distribution (VDss):** The **predicted steady-state volume of distribution is 1.00 L/kg**. A VDss of around 1 L/kg suggests moderate distribution into tissues, but it's not highly sequestered in peripheral tissues, nor is it confined solely to the plasma.
*   **Experimental Data:** A search for "4-nitrobenzofuroxan pharmacokinetics" in PubMed **did not yield any direct experimental data**. This indicates that comprehensive published pharmacokinetic studies on this specific compound may be limited or not indexed under this precise term in common scientific databases. Therefore, the current understanding of its PK properties relies primarily on *in silico* predictions.

In summary, 4-nitrobenzofuroxan is predicted to be a compound with rapid elimination (short half-life), moderate tissue distribution, and potentially poor oral absorption. The lack of readily available experimental PK data means these predictions should be interpreted with caution and would require *in vitro* and *in vivo* studies for validation.
============================================================
Rank: 10
Ligand Number: 16
SMILES: CC(C)C[C@@H]1C[C@@H](c2cccc(Br)c2)Nc2nnnn21
Confidence Score: 0.3702
Response: The PK properties of the drug CC(C)C[C@@H]1C[C@@H](c2cccc(Br)c2)Nc2nnnn21 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be 12.00 hours.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 13.00 L/kg, indicating extensive distribution into tissues.
============================================================
Rank: 11
Ligand Number: 0
SMILES: C1COCCN1NC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
Confidence Score: 0.3611
Response: Based on the provided predictions, the pharmacokinetic (PK) properties of the drug with SMILES C1COCCN1NC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-] are as follows:

*   **Absorption:** The predicted oral bioavailability is **less than 20%**. This indicates poor absorption from the gastrointestinal tract or significant first-pass metabolism, suggesting that oral administration might not be an efficient route for systemic delivery, and alternative routes (e.g., intravenous) might be necessary to achieve therapeutic concentrations.

*   **Distribution:** The predicted volume of distribution at steady state (VDss) is **33.00 L/kg**. This is a very high VDss, implying extensive distribution of the drug into tissues outside the plasma compartment. This often correlates with high lipophilicity and tissue binding, meaning the drug is widely distributed throughout the body's tissues and organs.

*   **Elimination:** The predicted half-life is **66.00 hours**. This is a very long half-life, indicating that the drug is eliminated slowly from the body. A long half-life means that it will take a considerable amount of time for the drug to be cleared, which could allow for less frequent dosing but also implies a prolonged time to reach steady-state concentrations and a potential for accumulation with repeated administration if not appropriately managed.
============================================================
Rank: 12
Ligand Number: 2
SMILES: Cc1ccc(CNc2ccc3nonc3c2[N+](=O)[O-])cc1
Confidence Score: 0.3009
Response: Based on the predictions, the drug with the SMILES Cc1ccc(CNc2ccc3nonc3c2[N+](=O)[O-])cc1 is predicted to have the following pharmacokinetic (PK) properties:

*   **Oral Bioavailability:** Less than 20%, suggesting poor absorption from the gastrointestinal tract.
*   **Half-Life:** Approximately 141.00 hours, indicating a very long elimination half-life.
*   **Steady-State Volume of Distribution (VDss):** 13.00 L/kg, which suggests extensive distribution into tissues.
============================================================
Rank: 13
Ligand Number: 14
SMILES: O=[N+]([O-])c1c(Nc2cc(F)cc(F)c2)ccc2nonc12
Confidence Score: 0.2936
Response: Based on the predictions, the pharmacokinetic properties of the drug O=[N+]([O-])c1c(Nc2cc(F)cc(F)c2)ccc2nonc12 are as follows:

*   **Oral Bioavailability:** It is predicted to have oral bioavailability of less than 20%.
*   **Steady-State Volume of Distribution (VDss):** The predicted steady-state volume of distribution is 2.00 L/kg.
*   **Half-Life:** The predicted half-life for this drug is 3.00 hours.
============================================================
Rank: 14
Ligand Number: 1
SMILES: O=[N+]([O-])c1c(NCc2ccccc2)ccc2nonc12
Confidence Score: 0.2824
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(NCc2ccccc2)ccc2nonc12 can be characterized as follows:

*   **Absorption (Oral Bioavailability):** The drug is predicted to have **poor oral bioavailability (<20%)**. This indicates that a very small fraction of the drug administered orally is expected to reach systemic circulation. This could be due to factors like poor permeability, extensive first-pass metabolism, or poor solubility in the gastrointestinal tract. To achieve therapeutic levels, alternative routes of administration or significantly higher oral doses might be required.
*   **Distribution (Volume of Distribution at Steady State, VDss):** The predicted VDss is **1.00 L/kg**. This value suggests a **moderate distribution** of the drug into body tissues. A VDss of around 1 L/kg indicates that the drug distributes beyond the plasma volume and into some peripheral tissues, but it is not extensively sequestered there.
*   **Elimination (Half-Life):** The drug is predicted to have a very long **half-life of 99.00 hours**. This indicates that the drug is eliminated very slowly from the body. A long half-life means that drug levels will remain elevated for an extended period, potentially allowing for less frequent dosing (e.g., once weekly or less). However, it also implies a longer time to reach steady-state concentrations and a prolonged risk of drug accumulation and potential side effects if dosing is not carefully managed.

While specific predictions for metabolism and excretion pathways were not directly obtained, the long half-life could suggest slow metabolism or slow excretion by the body. The presence of a nitro group in the structure may also indicate potential for reductive metabolism, which is a common biotransformation pathway for nitro compounds.

In summary, this drug exhibits challenging absorption characteristics but, once absorbed, is predicted to have a very long duration of action due to its slow elimination, with moderate tissue distribution.
============================================================
Rank: 15
Ligand Number: 15
SMILES: c1ccc([C@@H]2C[C@H](c3ccccc3)n3nnnc3N2)cc1
Confidence Score: 0.1600
Response: Based on the predictions obtained from cheminformatics tools for the drug with the SMILES string `c1ccc([C@@H]2C[C@H](c3ccccc3)n3nnnc3N2)cc1`, here are its key pharmacokinetic (PK) properties:

*   **Oral Bioavailability:** This drug is predicted to have **oral bioavailability less than 20%**. This indicates that a significant portion of an orally administered dose would likely not reach systemic circulation, suggesting potential challenges with oral administration or a need for higher doses to achieve desired therapeutic effects.

*   **Half-Life:** The predicted half-life (using the Obach model) is **322.00 hours**. This is an exceptionally long half-life, suggesting that the drug would persist in the body for an extended period. Such a long half-life could imply infrequent dosing schedules but also a long time to reach steady-state concentrations or to be eliminated from the body if adverse effects occur.

*   **Steady-State Volume of Distribution (VDss):** The predicted steady-state volume of distribution (using the Lombardo model) is **323.00 L/kg**. A very high volume of distribution like this indicates extensive distribution of the drug into various tissues and compartments throughout the body, outside of the plasma. This suggests that the drug is not confined to the bloodstream and may accumulate in tissues.

In summary, this drug is predicted to have poor oral bioavailability, a very long duration of action, and extensive tissue distribution. These properties would be crucial considerations for its formulation, dosing regimen, and potential clinical use.
============================================================
Rank: 16
Ligand Number: 13
SMILES: O=[N+]([O-])c1c(Nc2ccc(C(F)(F)F)cc2Cl)ccc2nonc12
Confidence Score: 0.1455
Response: Based on the predictions performed, the pharmacokinetic (PK) properties of the drug with SMILES O=[N+]([O-])c1c(Nc2ccc(C(F)(F)F)cc2Cl)ccc2nonc12 are as follows:

*   **Oral Bioavailability:** The drug is predicted to have oral bioavailability less than 20%. This suggests that only a small fraction of the orally administered dose may reach systemic circulation.
*   **Half-Life:** The predicted half-life is 1.00 hour. This indicates a relatively short duration of action, implying that frequent dosing might be required to maintain therapeutic levels.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 2.00 L/kg. A VDss in this range (typically 1-3 L/kg) suggests that the drug is moderately distributed into body tissues, but not extensively sequestered.
============================================================
Rank: 17
Ligand Number: 12
SMILES: O=[N+]([O-])c1c(Nc2cccc(F)c2)ccc2nonc12
Confidence Score: 0.1115
Response: Based on the performed predictions, the PK properties of the drug O=[N+]([O-])c1c(Nc2cccc(F)c2)ccc2nonc12 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be 310.00 hours (using the Obach Model), indicating a very long duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 21.00 L/kg (using the Lombardo Method), suggesting extensive distribution into tissues.
============================================================
Rank: 18
Ligand Number: 5
SMILES: O=[N+]([O-])c1c(NCc2cc(F)ccc2F)ccc2nonc12
Confidence Score: 0.0672
Response: The pharmacokinetic (PK) properties of the drug O=[N+]([O-])c1c(NCc2cc(F)ccc2F)ccc2nonc12 are predicted as follows:

*   **Oral Bioavailability:** The drug is predicted to have oral bioavailability less than 20%. This suggests poor absorption from the gastrointestinal tract, indicating that a significant portion of an orally administered dose may not reach systemic circulation.
*   **Half-Life:** The predicted half-life is 99.00 hours. This is a very long half-life, meaning the drug will remain in the body for an extended period, requiring less frequent dosing but potentially leading to drug accumulation with repeated administration.
*   **Volume of Distribution at Steady State (VDss):** The predicted VDss is 1.00 L/kg. This value indicates moderate distribution of the drug into tissues beyond the plasma. A VDss of around 1 L/kg suggests the drug distributes into total body water and some peripheral tissues, but is not highly sequestered in specific compartments like adipose tissue or highly bound to plasma proteins.
============================================================
Rank: 19
Ligand Number: 11
SMILES: O=[N+]([O-])c1cccc(Nc2ccc3nonc3c2[N+](=O)[O-])c1
Confidence Score: -0.0677
Response: Based on the predictions, here are the pharmacokinetic (PK) properties of the drug with the SMILES O=[N+]([O-])c1cccc(Nc2ccc3nonc3c2[N+](=O)[O-])c1:

*   **Oral Bioavailability:** The drug is predicted to have **oral bioavailability less than 20%**. This suggests that if administered orally, only a small fraction of the dose would reach systemic circulation, potentially indicating poor absorption or significant first-pass metabolism.
*   **Half-Life (Obach model):** The predicted half-life is **19.00 hours**. This indicates a relatively long elimination half-life, meaning the drug stays in the body for an extended period, which could support less frequent dosing.
*   **Steady-State Volume of Distribution (VDss Lombardo model):** The predicted VDss is **33.00 L/kg**. This is a very high volume of distribution, suggesting that the drug extensively distributes into tissues outside the plasma compartment. This could imply significant tissue binding or accumulation.

In summary, this drug is predicted to have low oral bioavailability, a long half-life, and extensive tissue distribution.
============================================================
